Long-Term Complications After Prostate Cancer Treatment Not Uncommon
By Elana Gotkine HealthDay Reporter
FRIDAY, Nov. 8, 2024 -- Prostate cancer (PCA) treatment is associated with increased rates of complications in the 12 years after treatment, according to a study published online Nov. 7 in JAMA Oncology.
Joseph M. Unger, Ph.D., from the Fred Hutchinson Cancer Center in Seattle, and colleagues characterized long-term treatment-related adverse effects and complications in patients treated for PCA versus a general population of older men using data from two large PCA prevention clinical trials linked with Medicare claims records. The analysis included PCA patients treated with prostatectomy or radiotherapy versus an untreated control group.
The study sample included 29,196 participants; 3,946 had PCA, of whom 655 and 1,056 were treated with prostatectomy and radiotherapy, respectively. The researchers found that the 12-year hazard risk for urinary or sexual complications was 7.23 and 2.76 times higher for those with prostatectomy and radiotherapy treatment, respectively, versus untreated participants. The risk for bladder cancer was significantly increased for those treated with radiotherapy (hazard ratio, 2.78), and the risk for radiation-specific outcomes, including radiation cystitis and radiation proctitis, was also significantly increased (hazard ratios, 131.47 and 87.91, respectively). Per 1,000 person-years, the incidence of any one of the 10 treatment-related complications was 124.26, 62.15, and 23.61 for prostatectomy, radiotherapy, and untreated controls, respectively.
"The magnitude of these risks, compared with the relatively small benefit found by randomized clinical trials of PCA screening and treatment, should be explicitly reflected in national cancer screening and treatment guidelines and be integral to shared decision-making with patients before initiation of prostate-specific antigen screening, biopsy, or PCA treatment," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
MicroRNA-Based Germline Signature Predicts RT-Induced Genitourinary Toxicity in Prostate Cancer
FRIDAY, April 18, 2025 -- A biomarker consisting primarily of microRNA-based germline biomarkers (mirSNPs), PROSTOX, is valid for predicting radiotherapy (RT)-induced...
Prostate Cancer Screening Program Beneficial in Top Decile of Polygenic Risk Score
MONDAY, April 14, 2025 -- A prostate cancer screening program involving participants in the top decile of risk according to a polygenic risk score identifies clinically...
NeuroSAFE Improves Erectile Function After Radical Prostatectomy
THURSDAY, April 3, 2025 -- Use of the NeuroSAFE technique, a standardized frozen section analysis that enables accurate real-time detection of positive surgical margins during...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.